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Impact Objectives
• Establish a working group of experts on antibiotic stewardship and 
research design to determine the best way to design, analyse and 
report antibiotic stewardship interventions 
• Formulate recommendations for the optimal design of future 
research in the field of antibiotic stewardship
Improving antibiotic 
stewardship
Professor Martin Llewelyn and Dr Valentijn Schweitzer discuss antibiotic stewardship and explain 
why there is an urgent need to develop recommendations for better research in this field 
Could you start by defining ‘antibiotic 
stewardship’ and explain why is it important?
ML: Antibiotic resistance is one of the 
greatest challenges facing the world. 
Bacteria are increasingly resistant to the 
antibiotics we use to treat and prevent 
common infections. Overuse of antibiotics 
in medical treatment is one major driver of 
antibiotic resistance. The term ‘antibiotic 
stewardship’ refers to using antibiotics 
in ways which minimises their impact on 
antibiotic resistance without compromising 
individual patient treatment – making 
sure that we will continue to be able to use 
effective antibiotics in the future. As much 
as 30 per cent of human antibiotic use may 
be unnecessary and healthcare systems 
around the world are aiming to achieve 
substantial reductions in unnecessary 
antibiotic prescribing through better 
antibiotic stewardship.
Currently, up to 80 per cent of published 
antibiotic stewardship studies are flawed in 
ways that mean their results are not robust. 
What are the primary reasons for this? 
ML: Previous studies have not impacted 
practice as much as they should for 
two main reasons. First, many have 
methodological limitations. Observational 
studies (where we just compare groups 
of patients who have been managed 
differently) dominate this field because 
experimental studies (where we directly 
intervene to change how patients are 
managed) are harder to undertake. 
Many forms of bias are inherent in these 
observational studies and frequently these 
are not addressed as well as they could 
be in study design. Second, most studies 
just do not consider outcomes relevant to 
the patients being treated, both in terms 
of their illness and of antibiotic resistance. 
Instead, they focus exclusively on ‘process 
outcomes’ (e.g. does my intervention 
reduce antibiotic use?). Few show that this 
happens without detriment to treatment 
outcome or that it actually results in less 
selection for resistance. 
How is your group working to help 
researchers overcome these limitations?
ML: We have done two things. First, we 
have undertaken a very broad overview 
of published research in this field. Where 
previous analyses have asked what the 
research tells us, we have asked what types 
of studies have been done and in what 
ways have they failed to deliver impactful 
findings. Second, we have brought together 
an international panel of researchers, 
statisticians and clinicians in this field. 
Together, we have developed a theoretical 
framework, a sort of roadmap, to guide the 
researchers designing these studies in the 
decisions they need to make and provide 
guidelines for different design features that 
researchers should aim to include in their 
studies. 
How will you ensure that these 
recommendations translate into the 
real-world improvement of antibiotic 
stewardship trials?
VS: During the process of formulating 
these recommendations, we made sure 
to involve key opinion leaders in the field 
of antimicrobial stewardship. If these 
opinion leaders review and approve our 
work, it will increase the uptake of the 
recommendations. 
Another way that real-world improvement 
can be achieved is if journals start 
considering these recommendations 
before considering studies for publication. 
Recently, the journal Clinical Microbiology 
and Infection published an editorial with 
the minimal quality requirements for 
stewardship studies. If more journals adopt 
this strategy, this may be an impulse for 
improvement and eventually the quality of 
the published literature on stewardship will 
improve. l
Professor Martin Llewelyn Dr Valentijn Schweitzer
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Overuse of antibiotics is a major problem worldwide. The Consensus on Antimicrobial Stewardship 
Evaluation (CASE) Working Group aims to improve the quality of research on antibiotic stewardship 
and, in so doing, promote better practice
Bacterial infections have assailed humans 
throughout history. In ancient times, 
application of mouldy bread was known 
to be an effective remedy for infected 
wounds. The antibiotic era began in 1928 
when Alexander Fleming discovered the 
antibiotic activity of penicillin produced 
by the penicillium bread mould. During 
a ‘golden era’ of antibiotic discovery 
which followed World War Two, several 
novel, distinct ‘classes’ of antibiotic were 
discovered. Today, more than 100 different 
antibiotic agents are in use, but most fall 
into a handful of these chemically highly 
related ‘classes’: beta-lactams like penicillin, 
aminoglycosides, fluroquinolones, 
macrolides, sulphonamides, tetracyclines 
and glycopeptides. Antibiotics are among 
the most frequently prescribed medications 
in modern medicine and have saved 
millions of lives by inhibiting the growth 
of infectious disease-causing bacteria. 
Antibiotics underpin much modern 
medicine since treatments like cancer 
chemotherapy, immunotherapies and many 
forms of surgery are only possible because 
antibiotics are available.
However, bacteria have lived with humans 
for millennia and adapt quickly. When an 
antibiotic is used, strains and species of 
bacteria which are resistant to the effect of 
the antibiotic have a survival advantage. 
Emergence of antibiotic-resistant bacteria 
is now a critical issue in medicine. This 
rapid emergence of resistant bacteria has 
endangered the efficacy of antibiotics, 
posing a substantial threat to human health 
and placing a significant financial burden on 
healthcare systems. 
Reducing medical use of antibiotics is 
one important way to reduce the selection 
pressure that drives resistance. Antibiotics 
can be overused in different ways, including 
prescribing an antibiotic when it is not 
necessary, prescribing more than one when 
one would be enough, prescribing broadly 
acting agents when more specific agents 
could be used, and continuing treatment 
longer than necessary. 
IMPROVING ANTIBIOTIC STEWARDSHIP
In all these different ways, a significant 
proportion of antibiotics currently 
prescribed to patients are unnecessary. It 
is now clearly established that overuse of 
antibiotics is associated with increased risk 
of antibiotic resistance, both in populations 
and in individual patients. The challenge is 
how to use antibiotics more prudently but 
still make sure that patients get the effective 
antibiotic treatment they need. The term 
‘antibiotic stewardship’ describes strategies 
to meet this challenge. 
According to Professor Martin Llewelyn, 
the problem is that we do not have the 
evidence we need to tell us which antibiotic 
stewardship strategies we should be using. 
‘The situation arises out of very real issues 
with how to design research studies in 
the field of antimicrobial stewardship,’ he 
explains. ‘There has been an exponential 
increase in the number of published papers 
in this field of research, but the quality 
of these data – measured by the simple 
criterion of “Would it actually change 
anyone’s practice?” – is very poor.’
Well-designed antimicrobial stewardship trials 
are essential to informing evidence-based 
practice. With this in mind, Llewelyn and 
colleagues from the University Medical Center 
Utrecht (Professor Marc Bonten, Dr Valentijn 
Schweitzer and Dr Henri van Werkhoven) 
and the University of Oxford (Professor 
Sarah Walker) launched the Consensus on 
Antimicrobial Stewardship Evaluation (CASE) 
Working Group. Their goal is to establish 
a consensus within the research world on 
how antimicrobial stewardship trials can 
be most effectively conducted. The group’s 
work has followed three distinct stages: stage 
one involved the systematic evaluation of 
existing methodologies used in antimicrobial 
stewardship trials, stage two involved 
optimising project design to maximise impact, 
and stage three involved identifying key 
questions (for example: what is the potential 
for the intervention to compromise clinical 
outcomes?). The researchers’ overarching aim 
is to contribute to understandings of how best 
to address antimicrobial resistance, improve 
research quality for future antimicrobial 
stewardship trials, and demonstrate to 
funders the importance of supporting these 
expensive yet profoundly vital studies. 
The team is comprised of a highly 
multidisciplinary team of experts. According 
to Dr Valentijn Schweitzer, a coordinator 
in the group, this was essential. ‘Even 
though the different disciplines (such 
as primary care, secondary care, critical 
and paediatrics) have a common goal 
in antimicrobial stewardship, there is 
not enough communication between 
the disciplines,’ he explains. ‘By using a 
multidisciplinary approach, we are able to 
learn from these experiences.’
A need for consensus
The first Consensus on Antimicrobial Stewardship 
Evaluation (CASE) Working Group meeting in 
Utrecht, March 2017.
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BIOS
Professor Martin Llewelyn is a consultant 
in infectious diseases at the Department 
of Microbiology and Infection, Brighton 
and Sussex University Hospitals NHS 
Trust, and Professor of Infectious Diseases 
at Brighton and Sussex Medical School, 
University of Sussex. His clinical practice, 
research and teaching focus on protecting 
patients from harm caused by healthcare 
associated and antibiotic-resistant 
infections. He currently leads a UK-wide 
cluster randomised trial of the Antibiotic 
Review Kit (ARK)-Hospital complex 
behaviour change intervention in hospital 
antibiotic stewardship (http://www.
arkstudy.ox.ac.uk/). 
Dr Valentijn Schweitzer is a medical doctor 
and PhD candidate at the Epidemiology 
of Infectious Diseases Department of 
University Medical Centre Utrecht. His PhD 
tract focuses on antimicrobial stewardship 
and community-acquired pneumonia 
under the guidance of Professor Marc 
Bonten. Schweitzer is currently involved in 
a large multicentre trial on stewardship in 
community-acquired pneumonia patients. 
After completing his PhD, he will start 
residency training in clinical microbiology.
RESEARCH RECOMMENDATIONS 
From this research, some key findings have 
emerged. The team has proposed a novel 
theoretical framework for antimicrobial 
stewardship trials where four aspects of the 
intervention must be evaluated: its basis 
in theory and evidence, the intervention 
setting, the intervention features and the 
intervention aims. The team then proposes 
a series of key design questions that the 
researchers should answer in order to make 
the best study design decisions. 
The final step is to set out a series of specific 
consensus recommendations for researchers. 
Already, several important insights have 
emerged. ‘We recommend that future studies 
should always specify a clinical outcome to be 
measured to address concern that reducing 
antibiotic exposure might be detrimental to 
the patients being treated. This should sit 
alongside process outcomes to show that 
the stewardship intervention has reduced 
antibiotic use in the way the intervention 
intended,’ Llewelyn reveals. ‘We also set a 
benchmark for situations in which large, 
multicentre, controlled studies are not feasible 
but there is still a need for evidence to guide 
practice. Single centre observational studies 
have the potential to deliver valuable evidence 
– but only when they include properly 
conducted interrupted time series analysis.’
At present, the CASE Working Group is 
taking steps to actively disseminate its 
guidance, for example through conferences 
and publications. By exposing its findings to 
a wide range of scientists and stakeholders, 
the group hopes to make a significant 
economic and societal impact. With an 
international research team that consists of 
experts in the fields of clinical stewardship, 
adult medicine, paediatrics, statistics and 
implementation research, Llewelyn believes 
that their guidance to other researchers will 
be both thorough and authoritative. 
SAVING LIVES 
If current antibiotic practices continue 
unchanged, it is estimated that bacteria 
will continue to become more resistant so 
that, by 2050, antimicrobial resistance will 
be responsible for up to 10 million annual 
deaths. This rise in morbidity does not just 
come at tremendous human cost; it will 
also lead to a reduction in Gross Domestic 
Product (GDP) of up to 3.5 per cent, costing 
the world an estimated US $100 trillion. 
No one wants these dreadful statistics 
to become a reality. The only way to stop 
antimicrobial resistance from progressing 
is to adopt an effective, evidence-based 
antibiotic stewardship approach – a feat that 
requires international consensus on best 
antimicrobial stewardship research practices. 
If the CASE Working Group’s 
recommendations are followed, the 
team anticipates stronger antimicrobial 
stewardship studies with far fewer 
limitations. ‘The potential impact is huge 
if our findings are translated into better 
antibiotic research,’ Llewelyn states. 
‘The key thing for us is getting the best 
research done to produce the evidence 
clinicians need to use antibiotics precisely.’ 
Convincing healthcare professionals to 
re-evaluate their views and prescription 
policies regarding antibiotics is an uphill 
battle. However, by coming together as a 
united front, researchers from all around 
the world can pave a way to stopping 
antimicrobial resistance growth and, in turn, 
save millions of patient lives.  l
The potential impact is huge if our findings are 
translated into better antibiotic research. The 
key thing for us is getting the best research done 
to produce the evidence clinicians need to use 
antibiotics precisely
